{"doi":"10.1101/2020.07.21.20159129","title":"Plasma amyloid, phosphorylated tau, and neurofilament light for individualized risk prediction in mild cognitive impairment","abstract":"Abstract We developed models for individualized risk prediction of cognitive decline in mild cognitive impairment (MCI), using plasma biomarkers of β-amyloid (Aβ), tau, and neurodegeneration. We included MCI patients from the Swedish BioFINDER study (n=148) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI; n=86 for model selection; n=425 for prognostic validation). The primary outcomes were longitudinal cognition and conversion to AD dementia, predicted by plasma Aβ42/Aβ40, P-tau181, and neurofilament light (NfL). A model which included P-tau181 and NfL, but not Aβ42/Aβ40, had the best performance (AUC=0.88 for four-year conversion to AD in BioFINDER, validated in ADNI). The prognostic ability of plasma biomarkers was stronger than a basic model of age, sex, education, and baseline cognition and similar to cerebrospinal fluid biomarkers. Plasma biomarkers, in particular P-tau181 and NfL, may be of high value to identify MCI individuals who will progress to AD dementia in clinical trials and in clinical practice.","journal":"medRxiv","year":2020,"id":125189,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7421,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":272068,"name":"Antoine Leuzy","orcid":"0000-0003-4542-7879","position":1,"is_corresponding":false},{"id":230950,"name":"Sebastian Palmqvist","orcid":"0000-0002-9267-1930","position":2,"is_corresponding":false},{"id":230943,"name":"Shorena Janelidze","orcid":"0000-0003-2869-8378","position":3,"is_corresponding":false},{"id":230949,"name":"Erik Stomrud","orcid":"0000-0002-0841-5580","position":4,"is_corresponding":false},{"id":570955,"name":"Pedro Pesini","orcid":"0000-0002-0656-2384","position":5,"is_corresponding":false},{"id":571848,"name":"Leticia Sarasa","orcid":null,"position":6,"is_corresponding":false},{"id":570956,"name":"José Antonio Allué","orcid":"0000-0002-5690-3618","position":7,"is_corresponding":false},{"id":570957,"name":"Nicholas K. Proctor","orcid":"0000-0003-1525-3580","position":8,"is_corresponding":false},{"id":27601,"name":"Henrik Zetterberg","orcid":"0000-0003-3930-4354","position":9,"is_corresponding":false},{"id":230948,"name":"Jeffrey L. Dage","orcid":"0000-0002-2192-1699","position":10,"is_corresponding":false},{"id":27600,"name":"Kaj Blennow","orcid":"0000-0002-1890-4193","position":11,"is_corresponding":false},{"id":230942,"name":"Niklas Mattsson","orcid":"0000-0002-8885-7724","position":12,"is_corresponding":false},{"id":65584,"name":"Oskar Hansson","orcid":"0000-0001-8467-7286","position":13,"is_corresponding":false},{"id":477197,"name":"Nicholas Cullen","orcid":"0000-0002-6257-3387","position":0,"is_corresponding":true}],"reference_count":30,"raw_metadata":null,"created_at":"2026-07-18T23:15:15.482227Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}